ReviewImmunotherapy2015
CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
Review in Immunotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?Journal of hematology & oncology · 2025Review
- The evolution of cancer immunotherapy: a comprehensive review of its history and current perspectives.Korean journal of clinical oncology · 2024Review
- Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy.Journal of immunology research · 2020Review
- Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy.International journal of molecular sciences · 2019Review
- Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.Leukemia & lymphoma · 2018Review
- A history of exploring cancer in context.Nature reviews. Cancer · 2018Review
- Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.Protein & cell · 2017Review
- New development in CAR-T cell therapy.Journal of hematology & oncology · 2017Review
- CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo.The Journal of clinical investigation · 2016Article
- The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.Nature reviews. Clinical oncology · 2016Review
- Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy.Biochemical Society transactions · 2016Review
- Combination cancer immunotherapies tailored to the tumour microenvironment.Nature reviews. Clinical oncology · 2016Review
- Overcoming Antigen Escape with CAR T-cell Therapy.Cancer discovery · 2015Article
- The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer.Frontiers in immunology · 2015Review
- Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors.Cancer journal (Sudbury, Mass.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Chimeric antigen receptor (CAR) T-cell therapy has recently come into the spotlight due to impressive results in patients with B-cell acute lymphoblastic leukemia. By targeting CD19, a marker expressed most B-cell tumors, as well as normal B cells, CAR T-cell therapy has been investigated as a treatment strategy for B-cell leukemia and lymphoma. This review will discuss the successes of this therapy for the treatment of B-cell acute lymphoblastic leukemia and the challenges to this therapeutic strategy. We will also discuss application of CAR T-cell therapy to chronic lymphocytic leukemia and other B-cell malignancies including a follicular lymphoma, diffuse large B-cell lymphoma, as well as acute and plasma cell malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.